Your browser doesn't support javascript.
loading
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials.
Haduong, Josephine H; Heske, Christine M; Allen-Rhoades, Wendy; Xue, Wei; Teot, Lisa A; Rodeberg, David A; Donaldson, Sarah S; Weiss, Aaron; Hawkins, Douglas S; Venkatramani, Rajkumar.
Affiliation
  • Haduong JH; Division of Oncology, Hyundai Cancer Institute, Children's Hospital Orange County, Orange, California, USA.
  • Heske CM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Allen-Rhoades W; Division of Pediatric Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Xue W; Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Teot LA; Department of Pathology, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
  • Rodeberg DA; Division of Pediatric Surgery, East Carolina University, Greenville, North Carolina, USA.
  • Donaldson SS; Department of Radiation Oncology, Stanford University, Stanford, California, USA.
  • Weiss A; Division of Pediatric Hematology-Oncology, Maine Medical Center, Portland, Maine, USA.
  • Hawkins DS; Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
  • Venkatramani R; Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Pediatr Blood Cancer ; 69(4): e29511, 2022 04.
Article in En | MEDLINE | ID: mdl-35129294
ABSTRACT
Children and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous population with variable overall survival rates ranging between approximately 6% and 100% depending on defined risk factors. Although the risk stratification of patients has been refined across five decades of collaborative group studies, molecular prognostic biomarkers beyond FOXO1 fusion status have yet to be incorporated prospectively in upfront risk-based therapy assignments. This review describes the evolution of risk-based therapy and the current risk stratification, defines a new risk stratification incorporating novel biomarkers, and provides the rationale for the current and upcoming Children's Oncology Group RMS studies.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rhabdomyosarcoma / Rhabdomyosarcoma, Embryonal Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Child / Humans Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2022 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rhabdomyosarcoma / Rhabdomyosarcoma, Embryonal Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Child / Humans Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2022 Document type: Article Affiliation country: Estados Unidos